Taking the pledge demonstrates a practitioner’s commitment to perform the Basics of Administration amidst public concern and debate over the safety of ketamine therapy.
Was Mr. Perry, whose struggles with substance abuse were widely known, a good candidate for a drug used to relieve depression? Doctors say his case raises thorny questions.
Amidst increased public interest and controversy around at-home ketamine, including recent reports that some telehealth companies offer self-administered subcutaneous treatment, the American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3), the largest society and think tank for ketamine practitioners, is releasing a summary of guidelines for at- home use.
From the Washington Post Article: “For Erin Amato, MD, interventional psychiatrist and medical director at Montana Psychiatry and Brain Health Center, the opportunity to help patients find relief from difficult-to-treat depression is both a professional calling and a personal mission.
Matthew Perry’s death from the effects of ketamine brought new scrutiny to the booming business to prescribe the powerful anesthetic to patients in clinics and online.
In the wake of Matthew Perry’s autopsy report, we are committed to creating and publishing guidelines for at-home ketamine use, which should only be practiced with a very specific patient profile and only in the context of a close relationship with a provider and in-office follow-up.
The American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3), the largest society and think tank for ketamine-based therapy practitioners, has announced the formation of a faculty of experts across multiple disciplines of ketamine therapy. The consortium of experts will serve as a faculty in three pillars – Community, Education, & Standards – with a mission of advancing ketamine-based treatments for mental and physical health.
Ketamine therapy is booming but clinics who treat people with depression and suicidal ideation say they’re being cut off from their supply.
When one of Melissa Whippo’s clients was assaulted in her home, the client wanted ketamine to help her process the trauma she was experiencing. But Whippo, a psychotherapist who offers ketamine-assisted therapy in Oakland, almost wasn’t able to provide that—because she was down to her last dose of the drug.
Recent breakthroughs in the use of ketamine are changing the landscape of emerging treatment options for patients managing pain and mood disorders. The wide range of information about ketamine in news articles, blogs, and magazines can be confusing to the public seeking to learn more.
Ketamine is an anesthetic used to sedate both humans and pets, and it’s a favorite of partygoers seeking a psychedelic high. Now it’s also the subject of an enormous amount of interest as a fast-acting treatment for depression and other serious mental health conditions.
The summer I was 26 years old, I moved into my parents’ home in the Chicago suburbs because I could no longer care for myself. I had been severely depressed for most of my life, but that summer five years ago, even the most mundane tasks became insurmountable. I spent days on the couch where I rarely spoke, my mind so dull I struggled to form words. I lay awake at night thinking, I can’t go on like this.
Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.
Ketamine is rapidly emerging as an incredibly effective and fast-acting mental health medicine. The drug first emerged after the synthesis of phencyclidine in 1956, an anesthetic for monkeys.
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, is pleased to provide an update on its psychedelic product programs as it relates to the clinical and commercial development of ketamine…
Low doses of ketamine are just as effective at treating trauma pain in emergency room patients as larger standard doses, according to a new study by researchers at Loyola University Medical Center in Chicago.
NEW YORK and TOKYO, March 16, 2021 /PRNewswire/ — Perception Neuroscience (Perception), an atai Life Sciences (atai) company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd. (Otsuka), announce a collaboration and licensing agreement for the development and commercialization of Perception’s lead molecule, PCN-101 (R-ketamine) in Japan as a potential treatment for mood disorders such as major depressive disorder (MDD) and treatment-resistant depression (TRD).